Henderson Jeffrey William - Insider Transactions
Insider Type
individual
Companies
2
Average
1,729,149
Total Txns
9
Long-Term
Annual Transaction Insights
| Year | Buy | Sell | Δ | Buy, USD | Sell, USD | Δ |
|---|---|---|---|---|---|---|
| 2025 | 1 | 8 | -7 | 350,430.00 | 1,378,719.35 | -1,028,289.35 |
| Total: | 1 | 8 | 9 | 350,430.00 | 1,378,719.35 | -1,028,289.35 |
Transactions
| Company | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Halozyme Therapeutics, Inc. Common Stock US40637H1095 |
60.34 USD |
4,297 Sold |
259,268 USD |
28/04/2025 | 28/04/2025 |
| Halozyme Therapeutics, Inc. Common Stock US40637H1095 |
61.00 USD |
200 Sold |
12,199 USD |
28/04/2025 | 28/04/2025 |
| Halozyme Therapeutics, Inc. Common Stock US40637H1095 |
64.05 USD |
503 Sold |
32,217 USD |
01/04/2025 | 01/04/2025 |
| Halozyme Therapeutics, Inc. Common Stock US40637H1095 |
57.93 USD |
1,795 Sold |
103,992 USD |
03/03/2025 | 03/03/2025 |
| Halozyme Therapeutics, Inc. Common Stock US40637H1095 |
59.12 USD |
3,205 Sold |
189,467 USD |
03/03/2025 | 03/03/2025 |
| Becton, Dickinson and Company Depositary Shares, each Representing a 1/20th Interest in a Share of 6.00% Mandatory Convertible Preferred Stock, Series B |
233.62 USD |
1,500 Bought |
350,430 USD |
10/02/2025 | 10/02/2025 |
| Halozyme Therapeutics, Inc. Common Stock US40637H1095 |
55.94 USD |
1,100 Sold |
61,537 USD |
03/02/2025 | 03/02/2025 |
| Halozyme Therapeutics, Inc. Common Stock US40637H1095 |
56.41 USD |
3,900 Sold |
219,980 USD |
03/02/2025 | 03/02/2025 |
| Halozyme Therapeutics, Inc. Common Stock US40637H1095 |
50.01 USD |
10,000 Sold |
500,060 USD |
06/01/2025 | 06/01/2025 |